Our Partners Toronto Innovation Acceleration Partners, TIAP (formerly MaRS Innovation) is the commercialization agent for 10 of Ontario’s leading academic institutions, including the University of Toronto and affiliated research hospitals and CAMH, and is located in the MaRS Discovery District complex in Toronto, Canada. Supported by its members and industry partners, TIAP is a transformational commercialization hub that turns research strengths into commercial opportunities through strategic partnerships, licensing and company creation. TIAP represents over $1.47 billion of R&D funding annually, a portfolio of more than 60 companies, $160M in outside risk capital, and is credited with creating over 400 jobs.For more information, please see www.tiap.caEvotec SE is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading academic institutions, pharmaceutical and biotechnology companies, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and fee-for-service work. Evotec operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.For more information, please see www.evotec.com

Our Partners

Toronto Innovation Acceleration Partners, TIAP (formerly MaRS Innovation) is the commercialization agent for 10 of Ontario’s leading academic institutions, including the University of Toronto and affiliated research hospitals and CAMH, and is located in the MaRS Discovery District complex in Toronto, Canada. Supported by its members and industry partners, TIAP is a transformational commercialization hub that turns research strengths into commercial opportunities through strategic partnerships, licensing and company creation. TIAP represents over $1.47 billion of R&D funding annually, a portfolio of more than 60 companies, $160M in outside risk capital, and is credited with creating over 400 jobs.

For more information, please see www.tiap.ca

Evotec SE is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading academic institutions, pharmaceutical and biotechnology companies, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and fee-for-service work. Evotec operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.

For more information, please see www.evotec.com